AMGN · Earnings call · 2026Q3T · Full report
Capital Expenditures
AMGEN INC · 2026-11-03 · Importance 50 · Surprise 24 · In source text
Amgen reported $600 million of capital expenditures in the third quarter of 2026, including investments at manufacturing sites in North Carolina, Ohio, and Puerto Rico. Management expects approximately $2.6 billion of capital expenditures for full-year 2026 to scale manufacturing capacity for commercial growth and prepare for a potential MariTide launch. The company said its capacity expansion is designed for larger quantities of protein and does not require reducing its biosimilars business.
Key facts
- Amgen continued to expect approximately $2.6 billion in 2026 capital expenditures to scale manufacturing capacity for commercial growth and prepare for a potential MariTide launch.
- Amgen invested $600 million in capital expenditures in Q3 2026.
- Amgen's Q3 2026 capital expenditures of $600 million included investments at U.S. manufacturing sites in North Carolina, Ohio, and Puerto Rico.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | -2.3% | Amgen continued to expect approximately $2.6 billion in 2026 capital expenditures to scale manufacturing capacity for commercial growth… |